Oncology · NSCLCTrial Updateclinicalmid-term

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

Importance8/ 10

ActionInvestigate

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/16/2026, 6:04:27 AM

Assessment confidence: 61% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The discontinuation of the Phase 3 study for Trodelvy and KEYTRUDA in NSCLC is a significant setback for both Merck and Gilead, impacting their competitive positioning in the oncology market. This event necessitates a reevaluation of their strategies and potential partnerships in this therapeutic area. Regulatory context from FDA (Oncology (Cancer)/Hematologic Malignancies Approval Notifications) supports the near-term read. Assessment grounded in 20 ranked evidence items (8 high-relevance).

Strategic Assessment

Portfolio teams should reassess the viability of Trodelvy in NSCLC and consider alternative strategies or partnerships. The strongest clinical anchor is A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) (ClinicalTrials.gov), sub-indication match (lung cancer); mechanism alignment (io ). In lung cancer, 5 regulatory and 3 competitive items passed relevance filtering for Merck.

Competitive Pressure

The most relevant competitive pressure comes from Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC (Humanexa Signals) — sub-indication match (lung cancer); entity match (oncology). Secondary pressure from Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study. This discontinuation may impact Gilead's positioning in the NSCLC market, as Trodelvy was being evaluated in combination with a leading immunotherapy.

Regulatory Outlook

Regulatory risk is concentrated around Oncology (Cancer)/Hematologic Malignancies Approval Notifications (FDA). Entity match (oncology); Regulatory pathway relevance (approval). The discontinuation may influence future regulatory submissions and the perceived viability of Trodelvy in combination therapies, potentially affecting label indications.

Key Risks

Elevated medium regulatory exposure for Merck could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.
Regulatory risk from FDA (Sunscreen: How to Help Protect Your Skin from the Sun) could weigh on Merck through agency review timelines and labeling constraints if follow-through weakens.

Key Opportunities

The failure to demonstrate significant efficacy could lead to a loss of market share for Gilead in the NSCLC segment, affecting revenue projections and competitive dynamics in oncology.
Upside for Merck may improve if A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Merck may improve if Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · NSCLC · Trial Update · These results position LORBRENA as a preferred standard of care over XALKORI in ALK-positive advanced NSCLC, potentially shifting treatment paradigms.
FDA does not issue approval announcements for every approval or drug label update that occurs in oncology and hematology. Please refer to Drugs@FDA for the latest approvals and prescribing information for specific products.

What Would Change This Assessment

This becomes more urgent if Monitor for further data releases from the study and any strategic shifts from Merck or Gilead regarding their NSCLC portfolios.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

Oncology (Cancer)/Hematologic Malignancies Approval Notifications
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (approval)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — INQOVI (SUPPL)
FDAmedium relevance
Entity match (oncology); Regulatory pathway relevance (nda)
FDA document
View source
Sunscreen: How to Help Protect Your Skin from the Sun
FDAmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death
FDAmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (IO )
FDA document
View source
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (non-small cell lung cancer)
FDA document
View source
Evaluation of Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Entity match (non-small cell lung cancer)
FDA document
View source
Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Program
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Entity match (oncology)
Merck and Gilead Provide Update on Phase 3 KEYNOTE-D46/EVOKE-03 Study
Merckmedium relevance
Entity match (merck)
FDA document
View source
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Merckmedium relevance
Entity match (merck)
FDA document
View source
FDA Approves KEYTRUDA Combinations for Adjuvant Treatment in Clear Cell RCC
Humanexa Signalslow relevance
Entity match (oncology)

CXCL13-expressing CD4(+) T cells coordinate the lymphocytes triad to promote the anti-tumor immunity in NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progression in vitro and in vivo.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Merck)
FDA document
View source
Trial watch: antibody-drug conjugates in cancer therapy.
PubMedmedium relevance
Entity match (oncology)
FDA document
View source
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source
Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients.
PubMedmedium relevance
Sponsor/company relevance (Merck)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Merck
Trodelvy
non-small cell lung cancer
Oncology

Commercial impact

high

The failure to demonstrate significant efficacy could lead to a loss of market share for Gilead in the NSCLC segment, affecting revenue projections and competitive dynamics in oncology.

Regulatory impact

medium

The discontinuation may influence future regulatory submissions and the perceived viability of Trodelvy in combination therapies, potentially affecting label indications.

What to watch

Monitor for further data releases from the study and any strategic shifts from Merck or Gilead regarding their NSCLC portfolios.

Recommended action

Investigate

Assign analyst review and cross-reference against active portfolio assets.